• Home
  • Equities
    • UK
    • Global
    • Europe
    • US
    • Asia
    • Emerging markets
    • Specialist
  • Bonds
  • Multi-asset
  • ESG
    • ESG
    • Sustainable Investment
    • Sustainable Investing
  • Funds
    • Unit trusts/OEICs
    • Investment Trusts
    • VCTs/EIS
    • Platforms
    • ETFs
    • Pensions
  • Regulation
  • Diversity
  • People moves
  • Events
  • Financial library
  • Industry blogs
  • Digital Edition
  • Newsletters
  • Sign in
    • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0) 1858 438800

      Email: [email protected]

      • Sign in
     
      • Account details
      • Newsletters
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
    • Newsletters
    • Facebook
    • YouTube
    • Instagram
  • Register
  • Events
    • Upcoming events
      event logo
      Investment Week Select 2021

      Investment Week is delighted to announce the first 2021 date of the popular Select event, taking place on the afternoon of 26th January!

      • Date: 26 Jan 2021
      • ONLINE, ONLINE
      event logo
      Sustainable and ESG Market Briefing

      This interactive briefings will bring together senior fund selectors with leading fund managers running sustainable and ESG strategies to hear how they are navigating this rapidly-evolving part of the market, cutting through the greenwash and where they are finding opportunities.

      • Date: 09 Feb 2021
      • ONLINE, ONLINE
      event logo
      UK Equities Market Briefing

      Industry commentators have forecast a turnaround in fortunes for the unloved UK market in 2021 as vaccines are rolled out and the country starts to recover from the Covid-19 pandemic, while the threat of a no-deal Brexit has now been removed. During this event, fund managers running portfolios investing across the market-cap spectrum will give their views on potential tailwinds for the UK market and identify where they are finding the most compelling value opportunities in a post-Brexit world.

      • Date: 23 Feb 2021
      • ONLINE, ONLINE
      event logo
      Professional Adviser Working Lunches 2021

      A series of invitation only "meet the manager" virtual lunches to discuss how a multi-asset strategy can benefit your clients and your business.

      • Date: 24 Feb 2021
      • ONLINE, ONLINE
      View all events
      Follow our events

      Sign up to receive email alerts about our events

      Sign up

  • White papers
    • Fidelity logo whitebackground1200 630px 1 120x194
      The ETF Evolution

      In this exclusive magazine exploring the evolution of quality and income ETF strategies, King reveals that each ETF follows an investment strategy developed by the group's in-house research team that leverages fundamental active insights to inform the factor definitions and applies portfolio construction principles to mitigate the unintended biases.

      Download
      7ded04ac5957a69da8d1df41c8f21a0c33988d8f 1 120x194
      A bet on the UK bounce back

      David Cumming, Aviva Investors' chief investment officer for equities, last year witnessed turbulent times for UK equities but he remains positive about the market in which he has a personal as well as a professional stake.

      Download
      Find white papers
      Search by title or subject area
      View all white papers
  • Industry blogs
  • Digital Edition
Investment Week
Investment Week
Sponsored by BMO
  • Home
  • Equities
  • Bonds
  • Multi-asset
  • ESG
  • Funds
  • Regulation
  • Diversity
  • People moves
  • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0) 1858 438800

    Email: [email protected]

    • Sign in
 
    • Account details
    • Newsletters
    • Contact support
    • Sign out
 
  • Trending
  • IW 18 Jan issue
  • Past IW issues
  • UK borrowing soars
  • IW Select: Register now
  • Consistent 50
  • Industry Voice

Industry Voice: Biotechnology - new price triggers, low valuations

  • Investment Week
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
0 Comments

The biotech sector has been churning out a new generation of drug treatment options.

2017 has been a pivotal year for Ionis Pharma. The US biotech firm finally achieved a market breakthrough with its proprietary antisense technology. With this technology, doctors can inhibit the production of endogenous proteins in a patient that have been identified as disease-causing proteins.

Success stories such as Ionis Pharma could lift the stock prices of other biotech companies that are on the verge of a major breakthrough. Heightened volatility in biotech share prices is a reflection of the vast opportunities and risks that come with groundbreaking clinical developments. Besides the bottom-line growth of the biotech companies that are already profitable and clinical data readouts, regulatory approval of new drugs may represent the third major trigger for biotech stocks. In our view 2017 promises to be a stellar year in this regard: FDA had already approved 26 new drugs by mid-August, 15 of which from the biotech sector. That number already exceeds the new biotech drugs that had been approved in all of 2016.

The rising number of marketed biotech products has kept sector sales growing at a brisk pace. Unlike the pharma companies, we believe biotech firms are not threatened by precipitous drops in income as billion-dollar branded products come off patent. For investors, we believe the sustained strong earnings momentum is keeping biotech valuations at attractive levels. According to consensus earnings estimates published by Bloomberg, the six largest biotech companies by market cap are trading at around 15 times their estimated earnings per share for 2018, about the same as the major US pharma companies. A glance at PEG ratios, or the 2018 P/E ratios divided by estimated earnings growth for 2018, reveals a telling difference though. The average PEG for the biotech stocks is around 1, while the pharma stocks' current PEG valuation is around 1.9. 

Despite our view of the sector's very good fundamentals, many investors are still reluctant to allocate a significant amount of money to the biotech sector. Persisting uncertainty regarding the future course of federal healthcare policy in the US is currently the darkest cloud hanging over the sector. How to keep medical treatment and services at affordable levels for health insurance payers will continue to be a hot topic on the political agenda in Washington for the foreseeable future. In our view,  the greater the flow of positive news on the company front, the less biotech stocks will be held back by political noise. Looking at just four disease indications, we believe the regulatory approval of new therapeutic agents could unleash a very high sales potential in each of these four areas, which are immuno-oncology, liver diseases, orphan or rare genetic diseases, and neuro disorders such as Alzheimer's.

We believe that Biotech has superseded the pharma industry as the hotbed of innovation in drug development. The Swiss investment company with a market capitalization of EUR 2.9 billion is, in our view, one of the investment pioneers in this sector, having invested in biotech companies since 1993.

BB Biotech expects the companies in its portfolio to report a significant average top-line growth until  2020. Unlike actively managed equity funds, BB Biotech does not use any sector index as a benchmark. We attribute its strong performance versus the Nasdaq Biotechnology Index to its portfolio strategy, and believe core portfolio positions act as an anchor of stability. Companies that qualify for the portfolio's selection of smaller positions that can be gradually built up over time will have presented convincing clinical data on novel drug candidates and marketing authorization should not be too far off. What we believe also sets BB Biotech apart from conventional actively managed funds is its generous payout. Investors can expect an annual dividend yield of about 5%. In addition, up to 5% of share capital will be bought back every year through a continual share buyback program.

BB Biotech will publish its Q3 results on October 20, 2017.

Interview with Dr. Daniel Koller

For more information, please contact:

Claude Mikkelsen

[email protected], +44  203 326 29 83, www.bbbiotech.com

 

Disclaimer

Bellevue Advisors LLP is an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority. This advertisement is directed at professional clients and eligible counterparties as defined by the FCA in the UK only. Past performance is not indicative of future results.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
  • Topics
  • Industry Voice
  • Industry Voice
  • Biotechnology
  • BB Biotech
blog comments powered by Disqus
Back to Top
Trustpilot

 

  • Contact us
  • Marketing solutions
  • About Incisive Media
  • Terms and conditions
  • Policies
  • Careers
  • Twitter
  • LinkedIn
  • Newsletters
  • Facebook
  • YouTube
  • Instagram

© Incisive Business Media (IP) Limited, Published by Incisive Business Media Limited, New London House, 172 Drury Lane, London WC2B 5QR, registered in England and Wales with company registration numbers 09177174 & 09178013

Digital publisher of the year
Digital publisher of the year 2010, 2013, 2016 & 2017
Loading